Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) that works by blocking cyclooxygenase enzymes, which are responsible for producing prostaglandins, the chemical messengers behind pain, inflammation, and fever. It belongs to a subclass called fenamates and has been available since the 1960s, mainly prescribed for menstrual pain, heavy periods, and mild-to-moderate pain from other causes. While it shares a basic mechanism with better-known painkillers like ibuprofen and naproxen, mefenamic acid has a distinct safety profile and a few quirks that set it apart.
How Mefenamic Acid Works
Like all NSAIDs, mefenamic acid reduces pain and inflammation by interfering with the body’s prostaglandin production. Prostaglandins are fatty compounds that act as local hormones: they sensitize nerve endings to pain, ramp up the inflammatory response, and help regulate body temperature. Mefenamic acid inhibits both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), although its overall anti-inflammatory punch is considered moderate compared to some other NSAIDs.1Molecular Pharmacology. Mefenamic Acid Shows Neuroprotective Effects and Improves Cognitive Impairment in in Vitro and in Vivo Alzheimer’s Disease Models That moderate profile turns out to matter for side effects, as you will see in the sections on safety.
What makes mefenamic acid particularly useful for menstrual complaints is that prostaglandins play a starring role in uterine cramping and in controlling how much the uterine lining bleeds during a period. By dialing down prostaglandin output in the uterus, mefenamic acid tackles both the pain and the volume of bleeding at the same time.
Menstrual Pain
Period pain, or primary dysmenorrhea, is the single most common reason mefenamic acid gets prescribed around the world. A classic study gave 35 women with severe menstrual cramps 500 mg of mefenamic acid every eight hours (up to three days per cycle) for three consecutive menstrual cycles. About 89% of them experienced complete relief of all dysmenorrhea symptoms across all treated cycles, compared to just 13% who felt even moderate relief on placebo.2PubMed Central. Treatment of primary dysmenorrhea with mefenamic acid Those numbers are striking, and they help explain why mefenamic acid remains a first-line option in many countries for women whose period pain disrupts daily life.
A large network meta-analysis comparing multiple NSAIDs for dysmenorrhea found that mefenamic acid performed on par with diclofenac, ibuprofen, naproxen, and several others for pain relief, and all of these were substantially better than aspirin. Where mefenamic acid stood out was safety: the analysis flagged it, along with tiaprofenic acid, as among the safest options in the NSAID class for treating menstrual pain.3PubMed Central. Comparison of the efficacy and safety of non-steroidal anti-inflammatory drugs for patients with primary dysmenorrhea: A network meta-analysis That favorable safety signal is one reason clinicians keep reaching for it even when newer alternatives exist.
Heavy Menstrual Bleeding
Mefenamic acid is also used to reduce excessively heavy periods, a condition sometimes called menorrhagia. The evidence here is solid, though the drug is not the strongest option available. One study of women with essential menorrhagia found that mefenamic acid cut average menstrual blood loss by about 40%.4PubMed. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia A randomized controlled trial published in the BMJ reported a more modest reduction of about 20%, while tranexamic acid, a different type of medication, reduced loss by roughly 54% in the same trial.5BMJ. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid
A separate comparison trial found that mefenamic acid reduced bleeding volume by about 55%, though the authors noted this result did not reach statistical significance in their particular sample.6PubMed Central. Comparison of Misoprostol and Mefenamic Acid on Reducing Menstrual Bleeding in Patients Suffering From Heavy Menstrual Bleeding Taken together, the data suggest mefenamic acid meaningfully reduces heavy bleeding, with reductions somewhere in the range of 20% to 55% depending on the population and study design. If you need the most aggressive bleeding reduction, tranexamic acid tends to outperform it. But mefenamic acid offers the advantage of treating both the cramps and the bleeding at once, which tranexamic acid does not do.
Other Pain and Inflammation Uses
Beyond gynecological complaints, mefenamic acid is prescribed for mild-to-moderate pain from headaches, dental procedures, soft tissue injuries, and musculoskeletal conditions. In rheumatoid arthritis, a head-to-head comparison with ibuprofen found no significant difference in analgesic or anti-inflammatory effect between the two at the dosages tested.7PubMed. Mefenamic acid compared with ibuprofen in the treatment of rheumatoid arthritis In practice, mefenamic acid is used less often than ibuprofen for general pain because ibuprofen is available over the counter in most countries and has a longer track record for broad pain management. Mefenamic acid tends to be reserved for situations where its dual action on pain and prostaglandin-mediated bleeding offers a specific advantage, or where a patient has had a good response to it in the past.
In some countries, mefenamic acid is also used as a fever reducer in children. This use is more common in parts of Asia and the Middle East, and less so in North America and Europe, where acetaminophen and ibuprofen dominate pediatric fever management. The antipyretic effect comes from the same prostaglandin suppression that drives its other actions.
Typical Dosage
For adults, the standard dose for menstrual pain is 500 mg taken initially, followed by 250 mg every six hours as needed. Some prescribing protocols use 500 mg every eight hours, as the dysmenorrhea study described above did. Treatment is generally limited to a maximum of seven days for pain, and often only the first two to three days of menstruation for period-related use. For heavy menstrual bleeding, the drug is typically started on the first day of the period and continued for three to five days.
Mefenamic acid should be taken with food or milk, because it can irritate the stomach lining when taken on an empty stomach. The capsules or tablets should be swallowed whole, not crushed. In children, dosing is weight-based and varies by country; your pharmacist or doctor will calculate the appropriate amount. The drug is generally not recommended for children under six months of age, and many guidelines restrict pediatric use to short courses for fever.
Common Side Effects
The most frequent side effects are gastrointestinal: stomach pain, nausea, diarrhea, and indigestion. These affect a meaningful minority of users and are the usual reason people stop taking the drug. Diarrhea is particularly associated with mefenamic acid compared to other NSAIDs, possibly because of its effects on prostaglandin-mediated fluid regulation in the gut. Taking the drug with food helps reduce stomach upset, but does not eliminate it entirely.
Other common complaints include headache, dizziness, and drowsiness. These tend to be mild and go away once the course is finished. Skin rashes occur occasionally. If you develop a rash while taking mefenamic acid, stop and contact your doctor, because rashes can sometimes signal a more serious hypersensitivity reaction developing.
Gastrointestinal Risks
All NSAIDs carry a risk of irritating or damaging the lining of the stomach and upper intestine, and mefenamic acid is no exception. Case reports have documented gastritis, duodenitis, and even bleeding ulcers in patients taking the drug. One published case described a woman who developed vomiting of blood and black tarry stools two weeks after starting mefenamic acid for osteoarthritis; investigation revealed an acutely bleeding ulcer in an unusual location, the third portion of the duodenum, along with inflammation of both the stomach and duodenum.8PubMed. Gastritis, duodenitis, and bleeding duodenal ulcer following mefenamic acid therapy The authors noted that mefenamic acid may cause serious upper GI complications more often than was previously assumed, given that the drug shares many of the chemical and pharmacological properties of aspirin.9JAMA Internal Medicine. Gastritis, Duodenitis, and Bleeding Duodenal Ulcer Following Mefenamic Acid Therapy
The practical takeaway is that if you have a history of stomach ulcers, GI bleeding, or inflammatory bowel disease, mefenamic acid is generally not a good choice. Even without that history, using it for longer than recommended or at higher doses raises the risk. Alcohol use compounds the problem. If you need prolonged NSAID therapy and have GI risk factors, your doctor may prescribe a gastroprotective drug alongside it or choose a different painkiller altogether.
Interactions With Blood Thinners and Other Drugs
One of the most clinically important interactions is with warfarin, the widely used blood thinner. Mefenamic acid enhances warfarin’s anticoagulant effect through a mechanism that is not fully understood, and expert reviews specifically recommend that patients on warfarin avoid mefenamic acid.10PubMed. Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance The combination raises the risk of dangerous bleeding, especially in the GI tract, where mefenamic acid is already capable of causing ulceration on its own.
Beyond warfarin, mefenamic acid can interact with lithium (raising lithium blood levels), certain blood pressure medications (reducing their effectiveness), and other NSAIDs (compounding both GI and kidney risks). It can also reduce the efficacy of low-dose aspirin when the two are taken together, which is relevant for people who take daily aspirin for heart protection. If you are on any regular medication, mention it to your prescriber before starting mefenamic acid, even for a short course.
Overdose and Seizure Risk
Mefenamic acid has an unusual and important toxicity profile in overdose. An analysis of cases reported to the United Kingdom’s National Poisons Information Service found that people who overdosed on mefenamic acid were far more likely to develop central nervous system toxicity than people who overdosed on other NSAIDs combined. The risk of convulsions was dramatically elevated, with an adjusted odds ratio of about 82 compared to other NSAID overdoses.11PubMed Central. Central nervous system toxicity of mefenamic acid overdose compared with other NSAIDs: an analysis of cases reported to the United Kingdom National Poisons Information Service The risk was dose-related: the more mefenamic acid ingested, the higher the chance of seizures.
A recent case report also highlighted that mefenamic acid poisoning can cause acute kidney injury, with one patient’s creatinine spiking to levels requiring close monitoring, though it eventually resolved without dialysis.12PubMed Central. Mefenamic Acid Poisoning Revisited: Central Nervous System Toxicity and Acute Kidney Injury The combination of seizures and kidney damage makes mefenamic acid overdose a medical emergency that requires hospital management. This seizure risk is specific enough to mefenamic acid that poison control centers treat it differently from overdoses of ibuprofen or naproxen. If someone has taken a large amount, call emergency services even if they seem fine initially, since seizures can develop with a delay.
A Rare but Serious Reaction: Hemolytic Anemia
Among all NSAIDs, mefenamic acid is the one most frequently linked to a rare blood disorder called autoimmune hemolytic anemia, where the body’s immune system mistakenly attacks and destroys its own red blood cells. A review of NSAID-induced hemolytic anemia found that while several drugs in the class could trigger the condition, mefenamic acid was the most commonly implicated, and the mechanism appears to be an autoimmune process similar to what is seen with the blood pressure drug methyldopa.13PubMed. Induction of hemolytic anemia by nonsteroidal antiinflammatory drugs
Case reports continue to appear, including one involving a three-year-old boy who developed acute hemolysis after being given mefenamic acid for fever.14International Journal of Contemporary Pediatrics. Mefenamic acid triggered autoimmune hemolytic anemia in a child: a rare case report The condition is uncommon enough that most prescribers will never encounter it, but it is worth knowing about, especially if you develop unexplained fatigue, yellowing of the eyes or skin, or dark-colored urine while taking the drug. These are signs of red blood cell destruction that warrant immediate medical attention.
Who Should Avoid Mefenamic Acid
Several groups of people should steer clear of the drug or use it only under close supervision:
- History of GI bleeding or ulcers: The gastrointestinal risks make mefenamic acid a poor fit for anyone with past stomach or intestinal ulceration.
- Kidney disease: NSAIDs reduce blood flow to the kidneys, and mefenamic acid can worsen existing kidney problems or cause acute kidney injury.
- Warfarin or other anticoagulants: The enhanced bleeding risk makes the combination dangerous.
- Late pregnancy: Like all NSAIDs, mefenamic acid can cause premature closure of a fetal blood vessel called the ductus arteriosus, and it may reduce amniotic fluid levels. It is generally contraindicated after about 30 weeks of pregnancy.
- Aspirin-sensitive asthma: People who develop breathing difficulties or swelling after taking aspirin may react similarly to mefenamic acid.
- Inflammatory bowel disease: NSAIDs can trigger flares of Crohn’s disease or ulcerative colitis.
For older adults, the risks of GI bleeding, kidney impairment, and cardiovascular events are all elevated with any NSAID, so mefenamic acid should be used at the lowest effective dose for the shortest possible time. This advice applies to the entire NSAID class, not just mefenamic acid.
Emerging Research on Brain Inflammation
One of the more intriguing areas of current research involves mefenamic acid’s effects on a specific component of the immune system called the NLRP3 inflammasome. This protein complex plays a key role in driving inflammation in the brain, and it has been implicated in conditions ranging from Alzheimer’s disease to the long-term cognitive damage that sometimes follows severe infections like sepsis.
In rodent models of Alzheimer’s disease, mefenamic acid completely reversed memory deficits and reduced brain inflammation to levels seen in healthy animals. The protective effect persisted even three weeks after the drug was stopped, suggesting the benefit was not simply from dampening ongoing inflammation but from interrupting a self-perpetuating cycle of damage.15Nature Communications. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models This inflammasome-blocking action appears to be separate from the standard COX-inhibiting mechanism that all NSAIDs share, and it seems to be particularly strong in fenamate-class drugs like mefenamic acid.
A more recent study extended this work to a rat model of sepsis-associated brain dysfunction, finding that chronic mefenamic acid treatment reduced inflammasome activation, lowered inflammatory markers, protected mitochondria in brain cells from oxidative damage, and improved long-term memory performance. The drug also reduced the accumulation of amyloid-beta, a protein associated with neurodegeneration.16PubMed. Mefenamic acid attenuates NLRP3-associated neuroinflammation and mitochondrial dysfunction and is associated with prevention of long-term cognitive impairment after sepsis
All of this is still in the animal-model stage, and there is a long road between promising results in mice and a proven therapy for humans. The GI side effects and seizure risk of mefenamic acid at the doses needed for chronic use would need careful evaluation. Still, the inflammasome findings have opened a new line of thinking about whether cheap, well-characterized existing drugs might be repurposed for neuroinflammatory conditions. Clinical trials in humans would be the necessary next step, and as of now, no one should be taking mefenamic acid in the hope of preventing dementia.